Natriumchlorid Fresenius Kabi (Sodium Chloride)

The solution supplies sodium and chloride ions directly into the bloodstream, raising extracellular osmolarity. This draws water from the intracellular and interstitial spaces into the vascular compartment, expanding plasma volume and correcting low serum sodium or chloride levels while maintaining physiological tonicity.

The dose is individualized by the prescribing clinician based on the patient’s fluid deficit, electrolyte status, body weight, and clinical condition. Dosing calculations consider the required volume of isotonic fluid and the concentration of sodium chloride needed to achieve therapeutic goals.

Limited specific data are available for this product in pregnancy or lactation. Because isotonic saline is a standard component of fluid therapy, it may be used when clearly needed, but the prescriber should weigh potential benefits against any theoretical risks and monitor maternal and fetal status closely.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Natriumchlorid Fresenius Kabi is a 0.9% sodium chloride injection, equivalent in concentration to other standard isotonic saline solutions. Its EU manufacturing origin ensures compliance with European pharmacopeial standards. Clinically, it offers the same efficacy as other 0.9% saline brands, with selection often based on supplier reliability, packaging, and regulatory preferences.

Store the product below 25 °C in its original packaging, protecting it from moisture and direct light. Do not freeze the solution. Before use, inspect the container for leaks or particulate matter, and allow the solution to reach room temperature if it has been refrigerated during transport.

The solution is given intravenously, either as a direct infusion or diluted in compatible IV fluids. Administration rate should be adjusted to the patient’s cardiovascular and renal status, and infusion sets should be primed to avoid air embolism. Peripheral or central venous access may be used depending on the required volume.

Serious risks include severe hypernatremia, which can cause neurological disturbances, fluid overload leading to pulmonary edema, and rare anaphylactoid reactions. Rapid infusion of large volumes in patients with compromised cardiac or renal function can precipitate these complications, so careful monitoring is essential.

Patients with known hypersensitivity to sodium chloride solutions, uncontrolled heart failure, severe renal impairment, or those at high risk of fluid overload should avoid routine use. Additionally, individuals receiving incompatible IV medications that may precipitate with chloride should be evaluated before administration.